Biotech entity

Gareth Thomas

Person

All 1 tracked stories fall under one category: pharma. HIV is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Gareth Thomas, all published on September 12, 2026.

Last mentioned: 2d ago

Entity pulse

Recent coverage · Gareth Thomas

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Gareth Thomas

All 1 tracked stories fall under one category: pharma. HIV is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Gareth Thomas, all published on September 12, 2026. Each carries 6 original sources on average.

Stories tracked
1
Sources per story
6

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Gareth Thomas. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. AIDS 2026 in Rio de Janeiro

    Thomas and Gabriel join the Tackle HIV campaign on Ipanema Beach to combat stigma around the virus.

  2. Gareth Thomas discloses HIV status

    The retired Welsh rugby star publicly announces he is HIV positive and becomes a global advocate for people living with HIV.

  3. Welton Gabriel diagnosed HIV-positive

    Gabriel tests positive and contracts a treatment-resistant strain after a partner stopped medication; it takes seven months to achieve control, including a switch from a hepatotoxic first-line drug.

Stories mentioning Gareth Thomas 1

Pharma Neutral

HIV Stigma Persists: 7 Months to Control a Drug-Resistant Strain

A drug-resistant HIV case reported from AIDS 2026 illustrates how treatment interruption and first-line liver toxicity complicate care — and why tolerability and resistance barriers still define antiretroviral differentiation. For biopharma, stigma-driven non-adherence is an upstream clinical risk that next-generation regimens must engineer around.

6 sources

Source: knpr.org · wvxu.org

Gareth Thomas is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.